Erasca (ERAS) Income from Continuing Operations (2020 - 2026)
Erasca posted quarterly Income from Continuing Operations of 183462000.0 for Q1 2026, down 492.46% year-on-year from 46746353.1 in Q1 2025, and down 531.8% on a QoQ basis from 29038000.0 in Q4 2025.
Erasca (ERAS) has 7 years of Income from Continuing Operations data on file, last reported at 183462000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 492.46% year-over-year to 183462000.0; the trailing twelve-month figure through Mar 2026 stood at 276951000.0 (down 77.57% YoY), and the FY2025 full-year result was 124546000.0, up 22.95% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 183462000.0, down from 29038000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 29038000.0 in Q4 2025 and bottomed at 183462000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 33199000.0 (2023), against an average of 49163764.71.
- The widest annual swing landed in 2023, when Income from Continuing Operations jumped 78.04%; it then slumped 492.46% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 135250000.0 in 2022, then surged by 78.04% to 29701000.0 in 2023, then declined by 2.45% to 30429000.0 in 2024, then grew by 4.57% to 29038000.0 in 2025, then sank by 531.8% to 183462000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 183462000.0 (Q1 2026), 29038000.0 (Q4 2025), and 30575000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | -183.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -183.46 Mn |
| Dec 31, 2025 | -29.04 Mn |
| Sep 30, 2025 | -30.58 Mn |
| Jun 30, 2025 | -33.88 Mn |
| Mar 31, 2025 | -30.97 Mn |
| Dec 31, 2024 | -30.43 Mn |
| Sep 30, 2024 | -31.37 Mn |
| Jun 30, 2024 | -63.20 Mn |
| Mar 31, 2024 | -35.02 Mn |
| Dec 31, 2023 | -29.70 Mn |
| Sep 30, 2023 | -30.36 Mn |
| Jun 30, 2023 | -31.78 Mn |
| Mar 31, 2023 | -33.20 Mn |
| Dec 31, 2022 | -135.25 Mn |
| Sep 30, 2022 | -35.49 Mn |
| Jun 30, 2022 | -35.61 Mn |
| Mar 31, 2022 | -36.46 Mn |
| Dec 31, 2021 | -30.97 Mn |
| Sep 30, 2021 | -46.07 Mn |
| Jun 30, 2021 | -28.21 Mn |
| Mar 31, 2021 | -19.63 Mn |
| Dec 31, 2020 | -66.93 Mn |
| Sep 30, 2020 | -11.16 Mn |
| Jun 30, 2020 | -7.25 Mn |